Strata Critical Medical (SRTA) Shares Outstanding (Weighted Average) (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $85.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $85.3 million, up 6.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.3 million (up 6.8% YoY), and the FY2025 annual result was $82.1 million, up 5.93% from the prior year.
• Shares Outstanding (Weighted Average) improved to $85.3 million in Q1 2026 per SRTA's latest filing, from $82.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $85.3 million in Q1 2026 and troughed at $70.8 million in Q1 2022.
• A 5-year average of $76.3 million and a median of $75.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) jumped 171.17% in 2022, then advanced 1.72% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $71.2 million in 2022, then grew by 3.21% to $73.5 million in 2023, then advanced by 5.41% to $77.5 million in 2024, then increased by 5.93% to $82.1 million in 2025, then gained by 3.94% to $85.3 million in 2026.
• Business Quant data shows SRTA's Shares Outstanding (Weighted Average) at $85.3 million in Q1 2026, $82.1 million in Q4 2025, and $82.5 million in Q3 2025.